Abstract
BackgroundGenomic instability and clonal evolution are hallmarks of progressing chronic myeloid leukemia (CML). Recently, we have shown that clonal evolution and blast crisis correlate with altered expression and activity of Separase, a cysteine endopeptidase that is a mitotic key player in chromosomal segregation and centriole duplication. Hyperactivation of Separase in human hematopoietic cells has been linked to a feedback mechanism that posttranslationally stimulates Separase proteolytic activity after imatinib therapy-induced reduction of Separase protein levels.Methods and ResultsIn search for potential therapy-responsive transcriptional mechanisms we have investigated the role of the transcription factor c-MYB for Separase expression in CML cell lines (LAMA-84, K562, BV-173) and in clinical samples. Quantitative RT-PCR and Western blot immunostaining experiments revealed that c-MYB expression levels are decreased in an imatinib-dependent manner and positively correlate with Separase expression levels in cell lines and in clinical CML samples. RNA silencing of c-MYB expression in CML cell lines resulted in reduced Separase protein levels. Gelshift and ChIP assays confirmed that c-MYB binds to a putative c-MYB binding sequence located within the ESPL1 promoter.ConclusionsOur data suggest that ESPL1/Separase is a regulatory target of c-MYB. Therefore, c-MYB, known to be required for BCR-ABL-dependent transformation of hematopoietic progenitors and leukemogenesis, may also control the Separase-dependent fidelity of mitotic chromosomal segregation and centriole duplication essential for maintenance of genomic stability.
Highlights
Genomic instability and clonal evolution are hallmarks of progressing chronic myeloid leukemia (CML)
Quantitative RT-PCR and Western blot immunostaining experiments revealed that c-MYB expression levels are decreased in an imatinib-dependent manner and positively correlate with Separase expression levels in cell lines and in clinical CML samples
Our data suggest that ESPL1/Separase is a regulatory target of c-MYB
Summary
Genomic instability and clonal evolution are hallmarks of progressing chronic myeloid leukemia (CML). ESPL1/Separase, a cysteine endopeptidase, is a key player of chromosomal segregation and centrosome duplication In mitotic anaphase, it accomplishes proteolytic cleavage of Cohesin, a “glue” multi-protein complex that is responsible for cohesion of sister chromatids and of mother and daughter centrioles, the perpendicular oriented core structures of centrosomes [1,2,3]. Separase is tightly regulated on both translational and posttranslational levels The latter includes multiple inhibitory mechanisms combining Securin binding, specific serine residue phosphorylation (pSer1126) by CyclinB1/CDK1, autocatalytic cleavage, and PP2A-dependent stabilization of Separase-bound Securin. All these mechanisms work together to prevent ectopic and unscheduled activation of intracellular Separase molecules [13,14,15,16]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.